Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma

被引:117
作者
Wiencke, John K.
Zheng, Shichun
Jelluma, Nanette
Tihan, Tarik
Vandenberg, Scott
Tamgueney, Tanja
Baumber, Rachel
Parsons, Ramon
Lamborn, Kathleen R.
Berger, Mitchel S.
Wrensch, Margaret R.
Haas-Kogan, Daphne Adele
Stokoe, David
机构
[1] Univ Calif San Francisco, Dept Neurol Surg, Lab Neurol & Mol Epidemiol, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Sch Med, Brain Tumor Res Ctr, San Francisco, CA 94143 USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA
[4] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA
[5] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA
[6] Columbia Univ, Inst Canc Genet, New York, NY USA
关键词
low-grade glioma; methylation; PKB/Akt; PTEN; secondary glioblastoma;
D O I
10.1215/15228517-2007-003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma multiforme (GBM) can present as either de novo or secondary tumors arising from previously diagnosed low-grade gliomas. Although these tumor types are phenotypically indistinguishable, de novo and secondary GBMs are associated with distinct genetic characteristics. PTEN mutations, which result in activation of the phosphoinositide 3-kinase (PI3K) signal transduction pathway, are frequent in de novo but not in secondary GBMs or their antecedent low-grade tumors. Results we present here show that grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas commonly display methylation of the PTEN promoter, finding that is absent in nontumor brain specimens and rare in de novo GBMs. Methylation of the PTEN promoter correlates with protein kinase B (PKB/Akt) phosphorylation, reflecting functional activation of the PI3K pathway. Our results also demonstrate frequent methylation of the PTEN promoter in grade III astrocytomas and secondary GBMs, consistent with the hypothesis that these tumors arise from lower grade precursors. PTEN methylation is rare in de novo GBMs and is mutually exclusive with PTEN mutations. We conclude that methylation of the PTEN promoter may represent an alternate mechanism by which PI3K signaling is increased in grade II and III gliomas as well as secondary GBMs, finding that offers new therapeutic approaches in these patients.
引用
收藏
页码:271 / 279
页数:9
相关论文
共 52 条
[1]   PTEN promoter methylation in sporadic thyroid carcinomas [J].
Alvarez-Nuñez, F ;
Bussaglia, E ;
Mauricio, D ;
Ybarra, J ;
Vilar, M ;
Lerma, E ;
de Leiva, A ;
Matias-Guju, X .
THYROID, 2006, 16 (01) :17-23
[2]   The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells [J].
Asano, T ;
Yao, YX ;
Zhu, JJ ;
Li, DH ;
Abbruzzese, JL ;
Reddy, SAG .
ONCOGENE, 2004, 23 (53) :8571-8580
[3]   PTEN methylation and expression in glioblastomas [J].
Baeza, N ;
Weller, M ;
Yonekawa, Y ;
Kleihues, P ;
Ohgaki, H .
ACTA NEUROPATHOLOGICA, 2003, 106 (05) :479-485
[4]   Altered methylation patterns in cancer cell genomes: Cause or consequence? [J].
Baylin, S ;
Bestor, TH .
CANCER CELL, 2002, 1 (04) :299-305
[5]   Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas [J].
Cairncross, JG ;
Ueki, K ;
Zlatescu, MC ;
Lisle, DK ;
Finkelstein, DM ;
Hammond, RR ;
Silver, JS ;
Stark, PC ;
Macdonald, DR ;
Ino, Y ;
Ramsay, DA ;
Louis, DN .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (19) :1473-1479
[6]   Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer [J].
Cappuzzo, F ;
Hirsch, FR ;
Rossi, E ;
Bartolini, S ;
Ceresoli, GL ;
Bemis, L ;
Haney, J ;
Witta, S ;
Danenberg, K ;
Domenichini, I ;
Ludovini, V ;
Magrini, E ;
Gregorc, V ;
Doglioni, C ;
Sidoni, A ;
Tonato, M ;
Franklin, WA ;
Crino, L ;
Bunn, PA ;
Varella-Garcia, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09) :643-655
[7]   Epigenetic and genetic alternation of PTEN in cervical neoplasm [J].
Cheung, TH ;
Lo, KWK ;
Yim, SF ;
Chan, LKY ;
Heung, MS ;
Chan, CS ;
Cheung, AYK ;
Chung, TKH ;
Wong, YF .
GYNECOLOGIC ONCOLOGY, 2004, 93 (03) :621-627
[8]   A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome [J].
Cools, J ;
DeAngelo, DJ ;
Gotlib, J ;
Stover, EH ;
Legare, RD ;
Cortes, J ;
Kutok, J ;
Clark, J ;
Galinsky, I ;
Griffin, JD ;
Cross, NCP ;
Tefferi, A ;
Malone, J ;
Alam, R ;
Schrier, SL ;
Schmid, J ;
Rose, M ;
Vandenberghe, P ;
Verhoef, G ;
Boogaerts, M ;
Wlodarska, I ;
Kantarjian, H ;
Marynen, P ;
Coutre, SE ;
Stone, R ;
Gilliland, DG .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (13) :1201-1214
[9]   Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991 [J].
Davis, FG ;
Freels, S ;
Grutsch, J ;
Barlas, S ;
Brem, S .
JOURNAL OF NEUROSURGERY, 1998, 88 (01) :1-10
[10]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037